141 related articles for article (PubMed ID: 35574612)
1. Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Nonmuscle-Invasive Bladder Cancer.
Kates M; Mansour AM; Lamm DL; Shore N; Maulhardt H; Wendt A; Verco J; Marin A; Dewnani K; Verco S; diZerega GS
J Urol; 2022 Oct; 208(4):821-829. PubMed ID: 35574612
[TBL] [Abstract][Full Text] [Related]
2. Local administration of large surface area microparticle docetaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects: preclinical and clinical studies.
Maulhardt H; Verco S; Baltezor M; Marin A; diZerega G
Drug Deliv Transl Res; 2023 Feb; 13(2):503-519. PubMed ID: 36058988
[TBL] [Abstract][Full Text] [Related]
3. Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer.
McElree IM; Steinberg RL; Martin AC; Richards J; Mott SL; Gellhaus PT; Nepple KG; O'Donnell MA; Packiam VT
J Urol; 2022 Sep; 208(3):589-599. PubMed ID: 35892270
[TBL] [Abstract][Full Text] [Related]
4. Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer.
Steinberg RL; Thomas LJ; Brooks N; Mott SL; Vitale A; Crump T; Rao MY; Daniels MJ; Wang J; Nagaraju S; DeWolf WC; Lamm DL; Kates M; Hyndman ME; Kamat AM; Bivalacqua TJ; Nepple KG; O'Donnell MA
J Urol; 2020 May; 203(5):902-909. PubMed ID: 31821066
[TBL] [Abstract][Full Text] [Related]
5. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy.
Barlow LJ; McKiernan JM; Benson MC
J Urol; 2013 Mar; 189(3):834-9. PubMed ID: 23123371
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral Injection of Large Surface Area Microparticle Taxanes in Carcinomas Increases Immune Effector Cell Concentrations, Checkpoint Expression, and Synergy with Checkpoint Inhibitors: A Review of Preclinical and Clinical Studies.
diZerega GS; Maulhardt HA; Verco SJ; Marin AM; Baltezor MJ; Mauro SA; Iacobucci MA
Oncol Ther; 2024 Mar; 12(1):31-55. PubMed ID: 38289576
[TBL] [Abstract][Full Text] [Related]
7. Should intravesical Bacillus Calmette-Guerin (BCG) treatment be administered to patients with T0 after repeat transurethral resection of bladder tumor in patients with high-risk non-muscle invasive bladder cancer?
Yuk HD; Jeong CW; Kwak C; Kim HH; Ku JH
PLoS One; 2018; 13(11):e0208267. PubMed ID: 30496283
[TBL] [Abstract][Full Text] [Related]
8. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin.
Sfakianos JP; Kim PH; Hakimi AA; Herr HW
J Urol; 2014 Feb; 191(2):341-5. PubMed ID: 23973518
[TBL] [Abstract][Full Text] [Related]
9. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
[TBL] [Abstract][Full Text] [Related]
10. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy.
Barlow L; McKiernan J; Sawczuk I; Benson M
BJU Int; 2009 Oct; 104(8):1098-102. PubMed ID: 19389012
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of intravesical Bacillus Calmette-Guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guérin treatment.
Alanee S; Sana S; El-Zawahry A; Peabody J; Pearce T; Adams N; Deebajah M; Crabtree J; Delfino K; McVary K; Robinson K; Rao K
World J Urol; 2021 Oct; 39(10):3807-3813. PubMed ID: 33966128
[TBL] [Abstract][Full Text] [Related]
12. Upper tract urothelial carcinoma following intravesical bacillus Calmette-Guérin therapy for nonmuscle-invasive bladder cancer: Results from a multi-institutional retrospective study.
Nishiyama N; Hotta H; Takahashi A; Yanase M; Itoh N; Tachiki H; Miyao N; Matsukawa M; Kunishima Y; Taguchi K; Kitamura H; Masumori N
Urol Oncol; 2018 Jun; 36(6):306.e9-306.e15. PubMed ID: 29550096
[TBL] [Abstract][Full Text] [Related]
13. Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes.
Gan C; Amery S; Chatterton K; Khan MS; Thomas K; O'Brien T
J Urol; 2016 Jun; 195(6):1697-703. PubMed ID: 26845426
[TBL] [Abstract][Full Text] [Related]
14. T1 Substaging of Nonmuscle Invasive Bladder Cancer is Associated with bacillus Calmette-Guérin Failure and Improves Patient Stratification at Diagnosis.
de Jong FC; Hoedemaeker RF; Kvikstad V; Mensink JTM; de Jong JJ; Boevé ER; van der Schoot DKE; Zwarthoff EC; Boormans JL; Zuiverloon TCM
J Urol; 2021 Mar; 205(3):701-708. PubMed ID: 33191862
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.
Fujita N; Hatakeyama S; Momota M; Kido K; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2020 Aug; 38(8):684.e17-684.e24. PubMed ID: 32278732
[TBL] [Abstract][Full Text] [Related]
16. Early Photodynamic Diagnosis Cystoscopy After Bacillus Calmette-Guérin (BCG) Induction for High-Risk Nonmuscle Invasive Bladder Cancer Significantly Increased the Detection of BCG Refractory Tumors.
Morelli M; Baboudjian M; Vanacore D; Gondran-Tellier B; McManus R; Karsenty G; Lechevallier E; Montanari E; Boissier R
J Endourol; 2021 Dec; 35(12):1824-1828. PubMed ID: 34107773
[No Abstract] [Full Text] [Related]
17. Intravesical BCG therapy with photodynamic diagnosis-guided transurethral resection of bladder tumors improves recurrence-free survival.
Nakagawa R; Nohara T; Naito R; Kadomoto S; Iwamoto H; Yaegashi H; Kawaguchi S; Shigehara K; Izumi K; Kadono Y; Mizokami A
Photodiagnosis Photodyn Ther; 2023 Jun; 42():103574. PubMed ID: 37080348
[TBL] [Abstract][Full Text] [Related]
18. Insignificant role of bacillus Calmette-Guérin maintenance therapy after complete transurethral resection of bladder tumor for intermediate- and high-risk non-muscle-invasive bladder cancer: Results from a randomized trial.
Nakai Y; Anai S; Tanaka N; Chihara Y; Haramoto M; Otani T; Nakagawa Y; Hirao Y; Konishi N; Fujimoto K
Int J Urol; 2016 Oct; 23(10):854-860. PubMed ID: 27416975
[TBL] [Abstract][Full Text] [Related]
19. [A Randomized Controlled Study of Intravesical Instillation Therapy of Bacillus Calmette-Guérin vs. Epirubicinin Treating Non-muscular Invasive Bladder Cancer].
Yang WX; Shao YX; Hu X; Xiong SC; Liu Y; Li X
Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Mar; 52(2):326-333. PubMed ID: 33829710
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guérin.
Morales A; Herr H; Steinberg G; Given R; Cohen Z; Amrhein J; Kamat AM
J Urol; 2015 Apr; 193(4):1135-43. PubMed ID: 25286009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]